Phase 3 N=23 Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage
Abscess
Primary: Number of Participants With Abscess Resolution — 11; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=161 Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management
Skin Diseases, Infectious
Primary: Skin Abscess Resolution — 4; 3 participants
Phase 2 N=92 Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage
Abscess · Cellulitis
Primary: Number of Participants Who Experienced a 30% or Greater Reduction in Surface Area of Abscess — 6; 19 Participants — p=.0003
Phase 2 N=20 Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses
Abdominal Abscess · Pelvic Abscess
Primary: Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage — 3; 7 participants
N/A N=31 Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
Abscess
Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants
N/A N=139 Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
Phase 3 N=212 Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses
Abscesses
Primary: Treatment Failures at 7 Days — 15; 27 participants
Phase 2 N=6 Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess
Furunculosis
Primary: Number of Side-effects — 4; 2 Participants
N/A N=265 Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage
Skin Disease, Bacterial · Abscess
Primary: Treatment Failures — 9; 4 participants — p=0.25
N/A N=200 Penicillin and Metronidazole in Treatment of Peritonsillar Abscess
Peritonsillar Abscess
Primary: Number of Participants With Recurrence of Peritonsillar Abscess — 10; 10 Participants — p=0.05
Phase 2 N=1,310 Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Staphylococcal Infection
Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…
Phase 4 N=50 Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the ED With Cutaneous Abscess
Cutaneous Abscess
Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants
N/A N=420 Emergency Bedside Ultrasound for Pediatric Soft Tissue Infections
Abscess
Primary: Sensitivity and Specificity of Bedside Emergency Ultrasound When Added to the Clinical Examination Compared With Clinical Examination Alone. — 94.7; 93.1; 84.2; 81.4…
N/A N=15 Hidradenitis Suppurativa (HS) Tunneling Wounds
Hidradenitis Suppurativa
Primary: Change in Microbiome — 5.46; 3.88 colony forming units per ml (CFU/ml)
Phase 2 N=32 Antibiotic Instillation in Appendicitis
Complicated Appendicitis · Acute Appendicitis
Primary: Feasibility of the Use of Antibiotic Solution Instillation Following Intraoperative Diagnosis of Complex Appendicitis as Assessed by Percentage of Eligible Participants…
Phase 4 N=40 Comparison of Excision Versus Punch Incision in the Treatment of Epidermal Cysts
Epidermal Cyst
Primary: Number of Participants With Cyst Recurrence — 3; 2 participants
Phase 2 N=104 Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction
Nonmalignant Breast Conditions · Breast Cancer
Primary: Number of Subjects With Drain Bulb Fluid Bacterial Colonization at Approximately 1 Week — 10; 21 participants — p=0.02
Phase 4 N=471 AUGMENTIN™ in Dental Infections
Focal Infection, Dental
Primary: Percentage of Participants Achieving Clinical Success (Cure or Improvement) Considering Clinical Judgment of the Investigator at the End of Treatment (Day 5 or Day 7)…
N/A N=102 Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis
Perforated Appendicitis
Primary: Abscess After Appendectomy — 10; 10 number of patients
Phase 2 N=20 Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus
Skin Infection
Primary: Status of Subject's Clinical Responses — 10; 1 participants
Phase 2 N=90 A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 26.1; 59.5; 57.3 Percentage of…
Phase 4 N=40 Optimal Care of Complicated Appendicitis
Appendicitis · Perforated Appendicitis · Ruptured Appendicitis
Primary: Overall Cost of Care
Phase 2 N=200 A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study
Major Cutaneous Abscess · Cellulitis · Erysipelas
Primary: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) — 91 participants
Phase 2 N=66 Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
Mycobacterium Infections, Nontuberculous · Mycobacterium Abscessus Infection · Nontuberculous Mycobacterial Lung Disease
Primary: Percentage of Participants With Clinical Response on NTM Symptom Assessment Scale at Day 84 — 34.1; 20.0 Percentage of participants — p=0.2182